Page 1066 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPter 76 Inflammatory Hepatobiliary Diseases 1029

On tHe HOrIZOn 17. Selmi C. The worldwide gradient of autoimmune conditions. Autoimmun
Rev 2010;9:A247–50.
Inflammatory hepatobiliary diseases remain an enigmatic and interesting 18. Podda M, Selmi C, Lleo A, et al. The limitations and hidden gems
group of tissue-specific autoimmune diseases, especially due to the of the epidemiology of primary biliary cirrhosis. J Autoimmun
frequent overlap among the different entities. However, primary biliary 2013;46:81–7.
cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune 19. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities
hepatitis (AIH) should be considered single diseases because the in primary biliary cirrhosis: a controlled interview-based study of 1032
pathogenesis, clinical manifestations, prognosis, and therapeutic patients. Hepatology 2005;42:1194–202.
approaches are different. Autoantibodies may help the clinician in the 20. Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary
diagnosis of the various diseases. However, it is important to remember cirrhosis: incidence, prevalence, and impact of therapy. J Clin
that there are limitations in the use of autoantibodies, especially due to Gastroenterol 2007;41:494–500.
variability in testing procedures, nonstandardized methods, and reporting. 21. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in
Treatment is changing along with new approaches to targeted therapies. monozygotic and dizygotic twins: genetics, epigenetics, and environment.
However, in most cases corticosteroids and ursodeoxycholic acid (UDCA) Gastroenterology 2004;127:485–92.
remain the cornerstones of therapy.
22. Miozzo M, Selmi C, Gentilin B, et al. Preferential X chromosome loss but
random inactivation characterize primary biliary cirrhosis. Hepatology
2007;46:456–62.
23. Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X
Please check your eBook at https://expertconsult.inkling.com/ in women with primary biliary cirrhosis. Lancet 2004;363:533–5.
for self-assessment questions. See inside cover for registration 24. Invernizzi P, Selmi C, Gershwin ME. Update on primary biliary cirrhosis.
details. Dig Liver Dis 2010;42:401–8.
25. Rieger R, Gershwin ME. The X and why of xenobiotics in primary biliary
cirrhosis. J Autoimmun 2007;28:76–84.
REFERENCES 26. Marzorati S, Lleo A, Carbone M, et al. The epigenetics of PBC: the link
1. Selmi C, Bowlus CL, Gershwin ME, et al. Primary biliary cirrhosis. Lancet between genetic susceptibility and environment. Clin Res Hepatol
2011;377:1600–9. Gastroenterol 2016;40:650–9.
2. Liberal R, Krawitt EL, Vierling JM, et al. Cutting edge issues in 27. Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary
autoimmune hepatitis. J Autoimmun 2016;75:6–19. biliary cirrhosis. Expert Rev Clin Immunol 2014;10:1667–78.
3. Jepsen P, Gronbaek L, Vilstrup H. Worldwide Incidence of Autoimmune 28. Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin Liver
Liver Disease. Dig Dis 2015;33(Suppl. 2):2–12. Dis 2003;7:779–94.
4. Vergani D, Mieli-Vergani G. Cutting Edge Issues in Autoimmune 29. Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation
Hepatitis. Clin Rev Allergy Immunol 2012;42:309–21. of the Mayo primary biliary cirrhosis survival model establishes its
5. Karlsen TH, Chung BK. Genetic Risk and the Development of generalizability. Hepatology 1989;10:846–50.
Autoimmune Liver Disease. Dig Dis 2015;33(Suppl. 2):13–24. 30. Agmon-Levin N, Shapira Y, Selmi C, et al. A comprehensive evaluation of
6. Mells GF, Kaser A, Karlsen TH. Novel insights into autoimmune liver serum autoantibodies in primary biliary cirrhosis. J Autoimmun
diseases provided by genome-wide association studies. J Autoimmun 2010;34:55–8.
2013;46:41–54. 31. Selmi C, Zuin M, Bowlus CL, et al. Anti-mitochondrial antibody-negative
7. Liberal R, Vergani D, Mieli-Vergani G. Update on Autoimmune Hepatitis. primary biliary cirrhosis. Clin Liver Dis 2008;12:173–85, ix.
J Clin Transl Hepatol 2015;3:42–52. 32. Invernizzi P, Selmi C, Ranftler C, et al. Antinuclear antibodies in primary
8. Zhao L, Tang Y, You Z, et al. Interleukin-17 contributes to the biliary cirrhosis. Semin Liver Dis 2005;25:298–310.
pathogenesis of autoimmune hepatitis through inducing hepatic 33. Olmez S, Sayar S, Avcioglu U, et al. The relationship between liver
interleukin-6 expression. PLoS ONE 2011;6:e18909. histology and noninvasive markers in primary biliary cirrhosis. Eur J
9. Liberal R, Grant CR, Longhi MS, et al. Diagnostic criteria of autoimmune Gastroenterol Hepatol 2016;28:773–6.
hepatitis. Autoimmun Rev 2014;13:435–40. 34. Hirschfield GM, Gershwin ME, Strauss R, et al. Ustekinumab for patients
10. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. with primary biliary cholangitis who have an inadequate response to
Hepatology 2006;43:S132–44. ursodeoxycholic acid: a proof-of-concept study. Hepatology
11. Cancado EL, Abrantes-Lemos CP, Terrabuio DR. The importance of 2016;64:189–99.
autoantibody detection in autoimmune hepatitis. Front Immunol 35. Mousa HS, Carbone M, Malinverno F, et al. Novel therapeutics for
2015;6:222. primary biliary cholangitis: toward a disease-stage-based approach.
12. Selmi C, Ceribelli A, Generali E, et al. Serum antinuclear and extractable Autoimmun Rev 2016;15:870–6.
nuclear antigen antibody prevalence and associated morbidity and 36. Bowlus CL. Cutting Edge Issues in Primary Sclerosing Cholangitis. Clin
mortality in the general population over 15 years. Autoimmun Rev Rev Allergy Immunol 2011;139–50.
2016;15:162–6. 37. Seo N, Kim SY, Lee SS, et al. Sclerosing Cholangitis: Clinicopathologic
13. Mullin S, Rabah R, Malas S, et al. Autoimmune Hepatitis Type 2 Features, Imaging Spectrum, and Systemic Approach to Differential
Associated With Positive Antimitochondrial Antibodies: An Overlap Diagnosis. Korean J Radiol 2016;17:25–38.
Syndrome? Clin Pediatr (Phila) 2016;55:479–82. 38. Hov JR, Lleo A, Selmi C, et al. Genetic associations in Italian primary
14. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. sclerosing cholangitis: heterogeneity across Europe defines a critical role
Nat Clin Pract Gastroenterol Hepatol 2007;4:202–14. for HLA-C. J Hepatol 2010;52:712–17.
15. Schramm C, Bubenheim M, Adam R, et al. Primary liver transplantation 39. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural
for autoimmune hepatitis: a comparative analysis of the European Liver history, and prognosis. Semin Liver Dis 2006;26:22–30.
Transplant Registry. Liver Transpl 2010;16:461–9. 40. Bjornsson E, Boberg KM, Cullen S, et al. Patients with small duct primary
16. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: sclerosing cholangitis have a favourable long term prognosis. Gut
from ‘cirrhosis’ to ‘cholangitis. Hepatology 2015;62:1620–2. 2002;51:731–5.